Want to see IN:PPLPHARMA full AI Analyst Report?
Top Page
Piramal Pharma Limited
(PPLPHARMA)
Select Model
Select Model
Rating:58Neutral
Price Target:
₹217.00
▲(12.64% Upside)
Action:Reiterated
Date:08/07/26
The score is primarily driven by mixed financial performance: strong revenue growth and improved cash generation are tempered by recurring loss years and inconsistent returns. Technicals are supportive due to a strong uptrend, but overbought signals add near-term risk. Valuation is weakened by a negative P/E and minimal dividend yield.
Positive Factors
Revenue scale-up
Sustained top-line growth over multiple years indicates expanding commercial traction across CDMO, hospital generics and OTC channels. Durable revenue scale supports higher capacity utilization, better fixed-cost absorption, and provides a foundation for reinvestment in tech, capacity and global customer relationships.
Negative Factors
Volatile profitability and loss years
Recurring swings to net losses undermine earnings quality and predictability. Volatile profits complicate capital allocation, raise credit risk during downturns, and can erode retained equity. If losses persist, they may force cost cuts or asset sales that impair long-term growth initiatives.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue scale-up
Sustained top-line growth over multiple years indicates expanding commercial traction across CDMO, hospital generics and OTC channels. Durable revenue scale supports higher capacity utilization, better fixed-cost absorption, and provides a foundation for reinvestment in tech, capacity and global customer relationships.
Read all positive factors
Piramal Pharma Limited (PPLPHARMA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹284.31B
Dividend Yield0.07%
Average Volume (3M)264.14K
Price to Earnings (P/E)―
Beta (1Y)0.80
Revenue Growth0.78%
EPS Growth-420.81%
CountryIN
Employees7,120
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-2.37
Shares Outstanding1,331,348,100
10 Day Avg. Volume501,791
30 Day Avg. Volume264,138
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)2.22
Price to Sales (P/S)2.04
P/FCF Ratio35.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.36
Revenue Forecast (FY)₹101.40B
Piramal Pharma Limited Business Overview & Revenue Model
Company Description
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facili...
How the Company Makes Money
Piramal Pharma Limited generates revenue primarily through three business lines:
1) Contract Development and Manufacturing (CDMO): The company earns fees by providing development, scale-up, and manufacturing services to pharmaceutical and biotech...
Piramal Pharma Limited Financial Statement Overview
Summary
Income Statement
52
Neutral
Balance Sheet
58
Neutral
Cash Flow
66
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 92.05B | 88.69B | 90.61B | 81.06B | 70.32B | 64.72B |
| Gross Profit | 32.91B | 23.83B | 54.89B | 48.48B | 40.32B | 37.91B |
| EBITDA | 10.81B | 9.96B | 16.49B | 13.67B | 8.94B | 12.60B |
| Net Income | -3.14B | -3.26B | 911.30M | 178.20M | -1.86B | 3.76B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 179.65B | 156.78B | 153.12B | 145.23B | 127.97B |
| Cash, Cash Equivalents and Short-Term Investments | 13.55B | 13.55B | 5.21B | 5.02B | 6.60B | 3.79B |
| Total Debt | 0.00 | 56.75B | 48.56B | 47.10B | 56.37B | 41.28B |
| Total Liabilities | -81.63B | 98.02B | 75.52B | 74.00B | 77.49B | 61.00B |
| Stockholders Equity | 81.63B | 81.63B | 81.25B | 79.11B | 67.73B | 66.97B |
Cash Flow | ||||||
| Free Cash Flow | 4.57B | 5.10B | 2.28B | 2.92B | -4.81B | -1.23B |
| Operating Cash Flow | 8.90B | 14.00B | 8.92B | 10.05B | 4.84B | 7.66B |
| Investing Cash Flow | -4.68B | -8.69B | -4.77B | -4.34B | -13.39B | -18.12B |
| Financing Cash Flow | -3.61B | 2.57B | -4.41B | -4.22B | 8.18B | 7.94B |
Piramal Pharma Limited Technical Analysis
Positive
192.65
Price Trends
184.97
Positive
173.76
Positive
171.42
Positive
Market Momentum
8.10
Positive
65.39
Neutral
66.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:PPLPHARMA, the sentiment is Positive. The current price of 192.65 is below the 20-day moving average (MA) of 205.57, above the 50-day MA of 184.97, and above the 200-day MA of 171.42, indicating a bullish trend. The MACD of 8.10 indicates Positive momentum. The RSI at 65.39 is Neutral, neither overbought nor oversold. The STOCH value of 66.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:PPLPHARMA.
Piramal Pharma Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ₹164.17B | 59.88 | ― | 0.61% | -6.72% | -22.67% | |
58 Neutral | ₹284.31B | -90.16 | ― | 0.08% | 0.78% | -420.81% | |
56 Neutral | ₹27.26B | 39.89 | ― | ― | -20.86% | -34.46% | |
56 Neutral | ₹114.33B | 36.76 | ― | 0.74% | 10.96% | 11.16% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | ₹164.31B | 74.05 | ― | 0.31% | -3.41% | -56.45% | |
49 Neutral | ₹674.12B | 122.22 | ― | 0.12% | 9.83% | 5.07% |
* General Sector Average
IN:PPLPHARMA
Piramal Pharma Limited
213.55
20.80
10.79%
IN:BIOCON
Biocon Limited
414.05
54.53
15.17%
IN:CONCORDBIO
Concord Biotech Ltd.
1,569.30
-125.59
-7.41%
IN:DCAL
Dishman Carbogen Amcis Ltd.
173.85
-104.60
-37.57%
IN:JUBLINGREA
Jubilant Ingrevia Ltd.
717.80
0.69
0.10%
IN:SYNGENE
Syngene International Ltd.
407.05
-258.37
-38.83%
Piramal Pharma Limited Corporate Events
Piramal Pharma Says Share Price Surge Driven by Market Dynamics, Not New Disclosures
Jun 23, 2026
Piramal Pharma Limited has clarified that a recent news article highlighting a more than 10% spike in its share price, reportedly linked to multiple global regulatory approvals, does not contain any material information requiring disclosure under ...
Piramal Pharma Receives FDA Form 483 With VAI Observations at U.S. Plant
May 10, 2026
Piramal Pharma Limited reported that the U.S. FDA conducted a Good Manufacturing Practices inspection at its Sellersville, U.S., facility from May 4 to May 8, 2026, resulting in a Form 483 with three observations classified as Voluntary Action Ind...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.